Skip to main content

Table 2 Changes of serum lipids, apoA5 and hs-CRP levels in two groups

From: The influence of statin-fibrate combination therapy on lipids profile and apolipoprotein A5 in patients with acute coronary syndrome

  Baseline After 6 weeks After 12 weeks
Statin group Combination group Statin group Combination group Statin group Combination group
TC (mmol/L) 4.85 ± 0.90 4.92 ± 0.83 4.22 ± 0.88* 3.75 ± 0.65 * 4.12 ± 0.76† 3.39 ± 0.30†§
TG (mmol/L) 1.97 ± 1.02 1.91 ± 0.87 1.74 ± 0.71* 1.24 ± 0.54 * 1.62 ± 0.63† 1.15 ± 0.48†§
LDL-C (mmol/L) 3.00 ± 0.43 3.04 ± 0.46 2.30 ± 0.53* 2.06 ± 0.28 * 2.21 ± 0.55† 1.93 ± 0.29†§
HDL-C (mmol/L) 0.89 ± 0.22 0.93 ± 0.14 1.00 ± 0.26* 1.10 ± 0.13 * 1.05 ± 0.20† 1.14 ± 0.08†§
ApoA5 (ng/ml) 49.49 ± 1.59 49.50 ± 2.48 61.48 ± 6.00* 66.03 ± 8.79* 67.4 ± 5.50† 73.2 ± 6.67†§
Hs-CRP (mg/L) 3.97 ± 3.52 3.89 ± 2.96 2.01 ± 0.94* 1.61 ± 0.32* 2.03 ± 1.54* 1.62 ± 0.63*
  1. Note: TC total cholesterol, TG triglycerides, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, ApoA5 apolipoprotein A5, hs-CRP high-sensitivity C-reactive protein.
  2. * p < 0.05, compared with baseline in the same group;
  3. p < 0.05, compared with 6 weeks in the same group;
  4. § p < 0.05, combination group versus statin group by repeated measures ANOVA analyses.